Apoe3 (Apolipoprotein E3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Apoe3 (Apolipoprotein E3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Apolipoprotein E3 (APOE3) is the most common allele of the APOE gene, representing the "gold standard" or reference allele for comparing the effects of APOE2 (protective) and APOE4 (risk-increasing). It serves as the benchmark for understanding how different APOE alleles influence Alzheimer's disease (AD) risk, lipid metabolism, and neural repair mechanisms [1][2].
APOE3 contains:
APOE3 represents the "wild-type" with balanced function:
APOE3 serves as the functional baseline for comparing other alleles [3]:
| Feature | APOE2 | APOE3 | APOE4 |
|---|---|---|---|
| AD Risk | Decreased | Baseline | Increased 3-4x |
| Aβ Clearance | Enhanced | Normal | Impaired |
| Lipid Binding | Reduced | Intermediate | Highest |
| Neuroinflammation | Anti-inflammatory | Neutral | Pro-inflammatory |
| Age of Onset | Delayed | Average | Earlier |
APOE3 serves as the reference allele for [5]:
APOE3 carriers exhibit:
Apoe3 (Apolipoprotein E3) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Apoe3 (Apolipoprotein E3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bu G (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience, 10(5), 333-344. https://doi.org/10.1038/nrn2620
Huang Y, et al. (2017). Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to analgesia. Current Opinion in Lipidology, 28(2), 139-147. https://doi.org/10.1097/MOL.0000000000000399
Mahley RW (2016). Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of Molecular Medicine, 94(7), 739-746. https://doi.org/10.1007/s00109-016-1418-z
Liu CC, et al. (2017). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 13(2), 106-118. https://doi.org/10.1038/nrneurol.2016.178
Yamazaki Y, et al. (2019). Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 15(9), 501-518. https://doi.org/10.1038/s41582-019-0224-y
Safieh M, et al. (2019). Apolipoprotein E: from lipid transport to neurobiology. Progress in Lipid Research, 75, 100993. https://doi.org/10.1016/j.plipres.2020.100993
Vitek MP, et al. (2012). APOE isoform-specific effects on neuroinflammation. Journal of Neuroinflammation, 9, 167. https://doi.org/10.1186/1742-2094-9-167